The Trump Effect On Drug Pricing: Uncertainty Is The Only Constant
Those “massive” price cuts US President Trump said would be announced this week? Never mind.
You may also be interested in...
“Authorized generics” for Gilead's leading hepatitis C brands stands out from prior, largely symbolic responses to the lower list prices. This is not a political move, but a business one. It is also the clearest demonstration yet of why pricing reforms are necessary if lower list prices are the policy goal.
HHS’ “First 100 Days” take on the drug pricing “Blueprint” is a novel use of a tried-and-true milestone for presidential action. But it is probably more enlightening to look at what has happened in the 1,000 days since drug pricing became the overwhelming focus of political attention.
Letters to several pharmacy benefit managers and wholesalers request information on whether middlemen have discouraged decrease in list prices.